Enterobacteriaceae
Abstract This review summarises the changing epidemiology of resistance to cephalosporins and fluoroquinolones among the Enterobacteriaceae since the 1980s and its potential impact on prescribing choices now and in the immediate future. Whilst multiresistant Enterobacteriaceae are not a novel proble...
Gespeichert in:
| Veröffentlicht in: | International journal of antimicrobial agents 2007-05, Vol.29, p.S9-S22 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S22 |
|---|---|
| container_issue | |
| container_start_page | S9 |
| container_title | International journal of antimicrobial agents |
| container_volume | 29 |
| creator | Denton, Miles |
| description | Abstract This review summarises the changing epidemiology of resistance to cephalosporins and fluoroquinolones among the Enterobacteriaceae since the 1980s and its potential impact on prescribing choices now and in the immediate future. Whilst multiresistant Enterobacteriaceae are not a novel problem for high-risk hospital units, such as intensive care, the emergence of Escherichia coli co-expressing extended-spectrum β-lactamases, such as CTX-M types, along with fluoroquinolone resistance in the community is starting to impact in situations where cephalosporins and ciprofloxacin were seen as reliable first-line choices. The reduction in effective options to treat these infections, particularly of the urinary tract and bacteraemia, is likely to result in increased prescribing of carbapenems, thus generating further selective pressure for carbapenemases and other mechanisms of carbapenem resistance in the future. |
| doi_str_mv | 10.1016/S0924-8579(07)72174-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68097525</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S092485790772174X</els_id><sourcerecordid>20638532</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-c6ab9627250f29e2e141e536e971b5a252a735b453c04263540cc3b27d4e62003</originalsourceid><addsrcrecordid>eNqFkDtLA0EURgdRTIw29lqKFqt37rwyjSLBFwQsVEg3zE5uYOJmN84kgv_ezQMFG6vbnHs-OIydcLjkwPXVC1iURV8Zew7mwiA3shjtsC7vGyyM5WKXdX-QDjvIeQrAlZBqn3W40coixy47vqsXlJrSh_ZEH8jTIdub-CrT0fb22Nv93evgsRg-PzwNbodFkNIuiqB9aTUaVDBBS0hcclJCkzW8VB4VeiNUKZUIIFELJSEEUaIZS9IIIHrsbOOdp-ZjSXnhZjEHqipfU7PMTvfBGoXqXxBBi74S2IJqA4bU5Jxo4uYpznz6chzcqppbV3OrJA6MW1dzo_bvdDuwLGc0_v3aZmqBmw1AbY_PSMnlEKkONI6JwsKNm_jvxPUfQ6hiHYOv3umL8rRZprqN7bjL6GAjWTnArA0j8Q2w9o4T</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20638532</pqid></control><display><type>article</type><title>Enterobacteriaceae</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Denton, Miles</creator><creatorcontrib>Denton, Miles</creatorcontrib><description>Abstract This review summarises the changing epidemiology of resistance to cephalosporins and fluoroquinolones among the Enterobacteriaceae since the 1980s and its potential impact on prescribing choices now and in the immediate future. Whilst multiresistant Enterobacteriaceae are not a novel problem for high-risk hospital units, such as intensive care, the emergence of Escherichia coli co-expressing extended-spectrum β-lactamases, such as CTX-M types, along with fluoroquinolone resistance in the community is starting to impact in situations where cephalosporins and ciprofloxacin were seen as reliable first-line choices. The reduction in effective options to treat these infections, particularly of the urinary tract and bacteraemia, is likely to result in increased prescribing of carbapenems, thus generating further selective pressure for carbapenemases and other mechanisms of carbapenem resistance in the future.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/S0924-8579(07)72174-X</identifier><identifier>PMID: 17659212</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Cephalosporins - therapeutic use ; Drug Resistance, Multiple, Bacterial ; Enterobacteriaceae ; Enterobacteriaceae - drug effects ; Enterobacteriaceae Infections - drug therapy ; Enterobacteriaceae Infections - epidemiology ; Enterobacteriaceae Infections - microbiology ; Escherichia coli ; Fluoroquinolones - therapeutic use ; Humans ; Infectious Disease ; Multiresistance ; Treatment options</subject><ispartof>International journal of antimicrobial agents, 2007-05, Vol.29, p.S9-S22</ispartof><rights>Elsevier B.V.</rights><rights>2007 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-c6ab9627250f29e2e141e536e971b5a252a735b453c04263540cc3b27d4e62003</citedby><cites>FETCH-LOGICAL-c449t-c6ab9627250f29e2e141e536e971b5a252a735b453c04263540cc3b27d4e62003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0924-8579(07)72174-X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17659212$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Denton, Miles</creatorcontrib><title>Enterobacteriaceae</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>Abstract This review summarises the changing epidemiology of resistance to cephalosporins and fluoroquinolones among the Enterobacteriaceae since the 1980s and its potential impact on prescribing choices now and in the immediate future. Whilst multiresistant Enterobacteriaceae are not a novel problem for high-risk hospital units, such as intensive care, the emergence of Escherichia coli co-expressing extended-spectrum β-lactamases, such as CTX-M types, along with fluoroquinolone resistance in the community is starting to impact in situations where cephalosporins and ciprofloxacin were seen as reliable first-line choices. The reduction in effective options to treat these infections, particularly of the urinary tract and bacteraemia, is likely to result in increased prescribing of carbapenems, thus generating further selective pressure for carbapenemases and other mechanisms of carbapenem resistance in the future.</description><subject>Cephalosporins - therapeutic use</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Enterobacteriaceae</subject><subject>Enterobacteriaceae - drug effects</subject><subject>Enterobacteriaceae Infections - drug therapy</subject><subject>Enterobacteriaceae Infections - epidemiology</subject><subject>Enterobacteriaceae Infections - microbiology</subject><subject>Escherichia coli</subject><subject>Fluoroquinolones - therapeutic use</subject><subject>Humans</subject><subject>Infectious Disease</subject><subject>Multiresistance</subject><subject>Treatment options</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkDtLA0EURgdRTIw29lqKFqt37rwyjSLBFwQsVEg3zE5uYOJmN84kgv_ezQMFG6vbnHs-OIydcLjkwPXVC1iURV8Zew7mwiA3shjtsC7vGyyM5WKXdX-QDjvIeQrAlZBqn3W40coixy47vqsXlJrSh_ZEH8jTIdub-CrT0fb22Nv93evgsRg-PzwNbodFkNIuiqB9aTUaVDBBS0hcclJCkzW8VB4VeiNUKZUIIFELJSEEUaIZS9IIIHrsbOOdp-ZjSXnhZjEHqipfU7PMTvfBGoXqXxBBi74S2IJqA4bU5Jxo4uYpznz6chzcqppbV3OrJA6MW1dzo_bvdDuwLGc0_v3aZmqBmw1AbY_PSMnlEKkONI6JwsKNm_jvxPUfQ6hiHYOv3umL8rRZprqN7bjL6GAjWTnArA0j8Q2w9o4T</recordid><startdate>20070501</startdate><enddate>20070501</enddate><creator>Denton, Miles</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20070501</creationdate><title>Enterobacteriaceae</title><author>Denton, Miles</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-c6ab9627250f29e2e141e536e971b5a252a735b453c04263540cc3b27d4e62003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Cephalosporins - therapeutic use</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Enterobacteriaceae</topic><topic>Enterobacteriaceae - drug effects</topic><topic>Enterobacteriaceae Infections - drug therapy</topic><topic>Enterobacteriaceae Infections - epidemiology</topic><topic>Enterobacteriaceae Infections - microbiology</topic><topic>Escherichia coli</topic><topic>Fluoroquinolones - therapeutic use</topic><topic>Humans</topic><topic>Infectious Disease</topic><topic>Multiresistance</topic><topic>Treatment options</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Denton, Miles</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Denton, Miles</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enterobacteriaceae</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2007-05-01</date><risdate>2007</risdate><volume>29</volume><spage>S9</spage><epage>S22</epage><pages>S9-S22</pages><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>Abstract This review summarises the changing epidemiology of resistance to cephalosporins and fluoroquinolones among the Enterobacteriaceae since the 1980s and its potential impact on prescribing choices now and in the immediate future. Whilst multiresistant Enterobacteriaceae are not a novel problem for high-risk hospital units, such as intensive care, the emergence of Escherichia coli co-expressing extended-spectrum β-lactamases, such as CTX-M types, along with fluoroquinolone resistance in the community is starting to impact in situations where cephalosporins and ciprofloxacin were seen as reliable first-line choices. The reduction in effective options to treat these infections, particularly of the urinary tract and bacteraemia, is likely to result in increased prescribing of carbapenems, thus generating further selective pressure for carbapenemases and other mechanisms of carbapenem resistance in the future.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>17659212</pmid><doi>10.1016/S0924-8579(07)72174-X</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-8579 |
| ispartof | International journal of antimicrobial agents, 2007-05, Vol.29, p.S9-S22 |
| issn | 0924-8579 1872-7913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68097525 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Cephalosporins - therapeutic use Drug Resistance, Multiple, Bacterial Enterobacteriaceae Enterobacteriaceae - drug effects Enterobacteriaceae Infections - drug therapy Enterobacteriaceae Infections - epidemiology Enterobacteriaceae Infections - microbiology Escherichia coli Fluoroquinolones - therapeutic use Humans Infectious Disease Multiresistance Treatment options |
| title | Enterobacteriaceae |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T04%3A39%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enterobacteriaceae&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=Denton,%20Miles&rft.date=2007-05-01&rft.volume=29&rft.spage=S9&rft.epage=S22&rft.pages=S9-S22&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/S0924-8579(07)72174-X&rft_dat=%3Cproquest_cross%3E20638532%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20638532&rft_id=info:pmid/17659212&rft_els_id=1_s2_0_S092485790772174X&rfr_iscdi=true |